The risk-escalation model: A principled design strategy for early-phase trials

Kennedy Institute of Ethics Journal

Volumn 24, Issue 2, 2014, Pages 121-139

  Hey, Spencer Phillips ^a   Kimmelman, Jonathan ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DECISION MAKING; ETHICS; HUMAN; HUMAN EXPERIMENT; METHODOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; STANDARDS; TREATMENT OUTCOME; TRENDS; UNCERTAINTY;

AMYOTROPHIC LATERAL SCLEROSIS; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DECISION MAKING; HUMANS; PATIENT SELECTION; RESEARCH DESIGN; RISK ASSESSMENT; THERAPEUTIC HUMAN EXPERIMENTATION; TREATMENT OUTCOME; UNCERTAINTY;

EID: 84903730726     PISSN: 10546863     EISSN: 10863249     Source Type: Journal    
DOI: 10.1353/ken.2014.0017     Document Type: Article

References (19)

1. Boulis, Nicholas M., Thais Federici, Jonathan D. Glass, J. Simon Lunn, Stacey A. Sakowski, and Eva L. Feldman. 2012. "Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis. " Nature Reviews Neurolog. 8: 172-76.
2. Carlo, Waldemar A., Edward F. Bell, and Michele C. Walsh. 2013. "Oxygen-Saturation Targets in Extremely Preterm Infants. " New England Journal of Medicin. 368 (20): 1949-50.
3. Djulbegovic, Benjamin. 2007. "Articulating and Responding to Uncertainties in Clinical Research. " Journal of Medicine and Philosoph. 32 (2): 79-98.
4. Dresser, Rebecca. 2009. "First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless. " Journal of Medical Ethic. 37 (1): 38-50.
5. Nature Biotechnology. 2006. "Consequences. " Editorial. Vol. 24: 368.
6. Halpern, Sydney A. 2006. Lesser Harms: The Morality of Risk in Medical Research. Chicago: University of Chicago Press.
7. Holden, Constance. 2009. "Fetal Cells Again?" Scienc. 326 (5951): 358-59.
8. Junghans, Richard P. 2010. "Strategy Escalation: An Emerging Paradigm for Safe Clinical Development of T Cell Gene Therapies. " Journal of Translational Medicin. 8: 55.
9. Kimmelman, Jonathan. 2007. "Stable Ethics: Enrolling Non-Treatment Refractory Volunteers in Novel Gene Transfer Trials. " Molecular Therap. 15 (11): 1904-06.
10. Kimmelman, Jonathan. 2012. "A Theoretical Framework for Early Human Studies: Uncertainty, Intervention Ensembles, and Boundaries. " Trial. 13: 173.
11. London, Alex John, Jonathan Kimmelman, and Marina Elena Emborg. 2010. "Beyond Access vs. Protection in Trials of Innovative Therapies. " Scienc. 328 (5980): 829-30.
12. Piantadosi, Steven. 2005. Clinical Trials: A Methodologic Perspective, 2nd ed. Hoboken, NJ: Wiley Interscience.
13. Scott, Sean, Janice E. Kranz, Jeff Cole, et al. 2008. "Design, Power, and Interpretation of Studies in the Standard Murine Model of ALS. " Amyotrophic Lateralal Sclerosi. 9: 4-15.
14. Sugarman, Jeremy, and Clifton O. Bingham. 2008. "Ethical Issues in Rheumatology Clinical Trials. " Nature Reviews Rheumatolog. 4: 356-63.
15. Tibbitts, Jay, Joy A. Cavagnaro, Christine A. Haller, Ben Marafino, Paul A. Andrews, and John T. Sullivan. 2010. "Practical Approaches to Dose Selection for First-in-Human Clinical Trials with Novel Biopharmaceuticals. " Regulatory Toxicology and Pharmacolog. 58 (2): 243-51.
16. van der Worp, H. Bart, David W. Howells, Emily S. Sena, et al. 2010. "Can Animal Models of Disease Reliably Inform Human Studies?" PLoS Medicin. 7 (3): e1000245.
17. Watson, James M. 2009. "A History Lesson for Stem Cells. " Scienc. 324 (5928): 727-28.
18. Weinfurt, Kevin P. 2007. "Value of High-Cost Cancer Care: A Behavioral Science Perspective. " Journal of Clinical Oncolog. 25 (2): 223-27.
19. Wirth, Edward, Jane S. Lebkowski, and Karen Lebacqz. 2011. "Response to Frederic Bretzner et al. 'Target Populations for First-in-Human Embryonic Stem Cell Research in Spinal Cord Injury'. " Cell Stem Cel. 8 (5): 476-78.